Alexandra Glucksmann is Chief Operating Officer and founding employee at Editas Medicine Inc., a gene editing company whose mission is to translate its genome editing technology into a novel class of human therapeutics. Previously, Dr. Glucksmann was Senior Vice President of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing innovative nanopharmaceutical tumor-targeting products. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of science positions with increasing responsibility, ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. She serves on the board of Women in the Enterprise of Science and Technology (WEST). Dr. Glucksmann was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a PhD with honors from The University of Chicago.